Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 53746-169

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 53746-169). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Of New York Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Memantine HCl Tablets Usp 1)

Chemical structure of Memantine hydrochloride, showing the bicyclic cage-like framework with amine (NH2) and hydrochloride (HCl) groups, as well as methyl (CH3) substituents.*

FDA Label Image

5 mg (30 cnt)

Label for Memantine Hydrochloride Tablets USP 5 mg film-coated tablets. The label indicates a package of 30 tablets, Rx only, distributed by Amneal Pharmaceuticals LLC, Bridgewater, NJ. Storage instructions are included along with a barcode. The NDC number visible is 53746-173-30.*

FDA Label Image

10 mg (30 cnt)

Memantine Hydrochloride Tablets, USP 10 mg film-coated tablets label by Amneal Pharmaceuticals of New York LLC. The label includes the NDC number 53746-169-30 and states a package size of 30 tablets. It provides storage instructions, dosage direction to see the package insert, and cautions to keep out of reach of children.*

FDA Label Image

Figure 1 (Memantine HCl Tablets Usp 2)

A line graph comparing mean change from baseline in ADCS-ADL scores over 28 weeks of treatment between Memantine HCl and placebo groups. The x-axis shows weeks of treatment (0, 4, 12, 28), and the y-axis represents mean change scores indicating clinical improvement or decline. Memantine HCl shows less clinical decline over time compared to placebo, with error bars indicating variability.*

FDA Label Image

Figure 2 (Memantine HCl Tablets Usp 3)

A cumulative percentage of patients line graph comparing the change from baseline in ADCS-ADL scores between Memantine hydrochloride and placebo groups. The x-axis represents ADCS-ADL change from baseline (ranging from +10 to -25), while the y-axis shows the cumulative percentage of patients (0 to 100%). Two lines illustrate the results: one for the placebo group marked with squares and another for the Memantine HCl group marked with circles.*

FDA Label Image

Figure 3 (Memantine HCl Tablets Usp 4)

A line graph depicting the mean change from baseline in SIB score over 28 weeks of treatment comparing Memantine HCl and placebo groups. The graph highlights trends of clinical improvement and decline, with Memantine HCl showing less decline in SIB score compared to placebo, and includes plotted error bars representing SEM.*

FDA Label Image

Figure 4 (Memantine HCl Tablets Usp 5)

A cumulative percentage of patients graph comparing Memantine HCl and placebo groups. The x-axis represents SIB change from baseline, and the y-axis shows cumulative percentage of patients. Two lines plot patient response trends, with Memantine HCl depicted by an open circle line and placebo by a filled square line.*

FDA Label Image

Figure 5 (Memantine HCl Tablets Usp 6)

A line graph comparing the mean (± SEM) change from baseline in ADCS-ADL score over 24 weeks of treatment between two groups: Placebo/Donepezil and Memantine HCl/Donepezil. The x-axis represents weeks of treatment, and the y-axis shows the mean change in score, with clinical improvement and decline indicated. Error bars show variability for each data point.*

FDA Label Image

Figure 6 (Memantine HCl Tablets Usp 7)

A cumulative percentage of patients graph comparing placebo/Donepezil and Memantine HCl/Donepezil treatment groups. The x-axis represents ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) change from baseline, and the y-axis shows cumulative percentage of patients. Two curves with distinct markers depict patient response distributions for each group.*

FDA Label Image

Figure 7 (Memantine HCl Tablets Usp 8)

A line graph showing mean change from baseline in SB Score over 24 weeks of treatment. It compares two groups: Placebo/Donepezil and Memantine HCl/Donepezil. The y-axis represents mean change with clinical improvement above and clinical decline below a zero baseline. The x-axis shows weeks of treatment from 0 to 24. Memantine HCl/Donepezil shows an increasing trend peaking around week 12, then declining, while Placebo/Donepezil remains near baseline or declines over time.*

FDA Label Image

Figure 8 (Memantine HCl Tablets Usp 9)

A cumulative percentage graph showing the change in SIB (Severe Impairment Battery) scores from baseline for two groups: Placebo/Donepezil and Memantine HCl/Donepezil. The x-axis represents the SIB change from baseline, ranging from positive to negative values, and the y-axis shows the cumulative percentage of patients, ranging from 0% to 100%. The graph compares the distribution of these changes for the two treatment groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.